Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05728359

Genomic Determinants of Outcome in Cardiogenic Shock

The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Barts Health NHS trust

London, United Kingdom

Location status: Recruiting

Location contact

Dan Jones

CONTACT

[email protected]

About this study

This is a prospective observational cohort study in 8-10 cardiac centres across Europe. We will recruit patients presenting with acute myocardial infarction (AMI) and CS who are supported medically (n=100); with extracorporeal membrane oxygenation (n=50); and with the Impella Device (n=50). We will also enrol patients who present with either AMI and no evidence of CS (n=50) or CS due to non-ischaemic pathologies (e.g. myocarditis: n=50) as comparators. The recruitment target is 300 patients.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All of the following are required for inclusion following screening:
  • Willing to provide informed consent or appropriate consent from a nominated consultee or personal consultee
  • Presentation within 24 hours of onset of ACS symptoms.
  • CS can only be secondary to ACS (Type 1 MI STEMI or N-STEMI) or myocarditis
  • Planned or completed revascularisation of culprit coronary artery

CS will be defined by:

  • Systolic blood pressure <90 mmHg for at least 30 minutes
  • A requirement for a continuous infusion of vasopressor or inotropic therapy to maintain systolic blood pressure > 90 mmHg.
  • Clinical signs of pulmonary congestion, plus signs of impaired organ perfusion with at least one of the following manifestations:
  • altered mental status.
  • cold and clammy skin and limbs.
  • oliguria with a urine output of less than 30 ml per hour.
  • elevated arterial lactate level of >2.0 mmol per litre.

Exclusion criteria

  • Any of the inclusion criteria not met and:
  • Unwilling to provide informed consent.
  • Echocardiographic evidence (recorded within 90 mins of end of PCI procedure) of mechanical cause for CS: eg ventricular septal defect, LV-free wall rupture, ischaemic mitral regurgitation.
  • Age <18 and ≥80 years.
  • Shock from another cause (sepsis, haemorrhagic/hypovolaemic shock, anaphylaxis, etc).
  • Significant systemic illness
  • Known dementia of any severity
  • Comorbidity with life expectancy <12 months.
  • Out-of-hospital cardiac arrest (OHCA) and any of the following:
  • No return of spontaneous circulation (ongoing resuscitation effort)
  • pH <7
  • Without bystander CPR within 10 minutes of collapse
  • Arterial lactate level of <2.0 mmol per litre.

Treatment and study plan

observational study

Other

Blood sampling and clinical data collection

Primary outcomes

  1. The primary aim is to better understand the heterogeneity of the immune consequences and treatment responses in CS through identification of transcriptomic sub-phenotypes and their association with in-hospital mortality

    Time frame: through study completion, an average of 5 days

    This will be achieved through bloods sample collection, analysis and linked to the patient's clinical diagnosis and outcome.

Secondary outcomes

  1. Identify transcriptomic (and chemokine/cytokine) signatures at presentation that elucidate the pathobiology of CS and examine their subsequent evolution.

    Time frame: through study completion, an average of 5 days

    Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.

  2. Correlate recently identified clinical phenotypes of CS with transcriptomic and inflammatory mediator signatures.

    Time frame: through study completion, an average of 5 days

    Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.

  3. Identify transcriptomic and chemokine/cytokine signatures at presentation that improve prognostic accuracy in patients with CS

    Time frame: through study completion, an average of 5 days

    Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.

  4. Investigate inter-individual heterogeneity in the dynamic transcriptomic response to CS through an eQTL mapping approach and identify context- specific regulatory genetic variants involving gene networks central to the pathogenesis of CS.

    Time frame: through study completion, an average of 5 days

    Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.

  5. Identity novel therapeutic targets that might modulate the dysfunctional immune response to CS - "drug discovery"

    Time frame: through study completion, an average of 5 days

    Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.

  6. Determine the extent to which the signatures and drivers of a dysfunctional immune response in CS are shared with other critical illness syndromes.

    Time frame: through study completion, an average of 5 days

    Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.

Study contacts

Contact information is provided by the study sponsor or research team.

Alastair Proudfoot

CONTACT

[email protected]

02037658707

Mervyn Andiapen

CONTACT

[email protected]

02037658707

Sponsors and collaborators

Lead sponsor

Barts & The London NHS Trust

Other

Collaborators

  • University of Oxford

Registry information

Official study title

Prospective Observational Study Investigating Genomic Determinants of Outcome From Cardiogenic Shock (GOlDilOCS)

Acronym: Goldilocs

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Feb 15, 2023
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.